We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Manage Adverse Events From PI3K Inhibitors for Breast Cancer.
- Authors
Becze, Elisa
- Abstract
The article informs about PBK inhibitors as a new treatment option for postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer with the U.S. Food and Drug Administration's approval of alpelisib in combination with fulvestrant. Topicsinclude alpelisib remains the only PBK inhibitor approved today, others are in clinical trials; and role in facilitating communication among providers and explaining management recommendations to patients.
- Subjects
HYPERGLYCEMIA; PHOSPHOTRANSFERASES; DRUG side effects; BREAST tumors; CHEMICAL inhibitors
- Publication
ONS Voice, 2021, Vol 36, Issue 3, p20
- ISSN
2475-6938
- Publication type
Article